We signed a worldwide re-license right agreement of the innovative modified nucleic acid technology targeting multiple genes in specific diseases with Aligos Therapeutics, Inc.

We believe this agreement would be the first step that the nucleic acid technologies, invented by Academia, would be widely promoted overseas to discover oligonucleotide therapeutics.

Please click here for details.